Symptoms of ipilimumab induced hypophysitis

What is the clinical presentation for ipilimumab-induced hypophysitis (IH)?

The diagnosis of IH is presumptive and based on the presence of new-onset hypopituitarism in medically-treated patients, and without an alternative etiology. It is most commonly observed in older males (mean age 55 years) and after ≈ 3 months (or 3–4 cycles) of treatment. Clinically, patients typically present with headaches (84%), fatigue (66%), and hyponatremia (56%). Biochemically, central hormone deficiencies are commonly observed for the thyroid (93%), gonadal (85%), and adrenal (75%) axes, and less commonly for GH (28%), and prolactin (25%). Conversely, ADH deficiency is very rarely observed (< 1%). The absence of DI is a distinct clinical feature of IH, in contrast to other forms of hypophysitis and metastatic disease of the posterior pituitary gland/stalk. Radiographically, heterogeneous mild pituitary gland enhancement, or stalk thickening are common, although the MRI may also be normal.

On a positive note, the development of IH generally predicts a more effective anticancer response and survival is improved in patients with melanoma treated with ipilimumab who develop IH.


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top